Bausch + Lomb Initiates Clinical Trial Evaluating New Ophthalmic Viscosurgical Device

Source: Bausch + Lomb

Bausch + Lomb announced that it has initiated a clinical trial evaluating the safety and efficacy of a new ophthalmic viscosurgical device (OVD). Bausch + Lomb aims to file for premarket approval (PMA) with the FDA at the conclusion of the clinical trial, with plans to bring this next-generation OVD to the United States market in 2019.

“OVDs play a critical role in ophthalmic surgery, and selection is highly individualized based on clinical surgical requirements and the surgeon’s preferences,” Chuck Hess, vice president and general manager, US Surgical, Bausch + Lomb, said in a company news release. “Our goal is to provide surgeons with a new option as part of our commitment to delivering innovations that expand their cataract surgery armamentarium.”


Related Content